Litcius/Paper detail

CTLA-4 Blockade Resistance after Relatlimab and Nivolumab

Alexander M. Menzies, Ines Pires da Silva, Claudia Trojaniello, Elisabeth Vieu, Rodabe N. Amaria, Lisa Zimmer, Serigne N. Lo, Elizabeth M. Burton, Hussein A. Tawbi, Dirk Schadendorf, Jean J. Grob, Paolo A. Ascierto, Georgina V. Long

2022New England Journal of Medicine26 citationsDOI

Abstract

kein CA

Topics & Concepts

NivolumabMedicineBlockadeCancer researchImmunotherapyInternal medicinePharmacologyPD-L1Drug resistanceAntibodyOncologyAcquired resistanceCancerImmune checkpointImmune systemCancer Immunotherapy and BiomarkersT-cell and B-cell ImmunologyMelanoma and MAPK Pathways
CTLA-4 Blockade Resistance after Relatlimab and Nivolumab | Litcius